- Home
- JYD vs PHGE Comparison
JYD vs PHGE Comparison
Compare JYD & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- PHGE
- Stock Information
- Founded
- JYD 2001
- PHGE 2015
- Country
- JYD China
- PHGE Israel
- Employees
- JYD N/A
- PHGE N/A
- Industry
- JYD Oil Refining/Marketing
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- JYD Consumer Discretionary
- PHGE Health Care
- Exchange
- JYD Nasdaq
- PHGE Nasdaq
- Market Cap
- JYD 18.9M
- PHGE 15.5M
- IPO Year
- JYD 2023
- PHGE N/A
- Fundamental
- Price
- JYD $4.87
- PHGE $0.58
- Analyst Decision
- JYD
- PHGE Strong Buy
- Analyst Count
- JYD 0
- PHGE 1
- Target Price
- JYD N/A
- PHGE $15.00
- AVG Volume (30 Days)
- JYD 77.3K
- PHGE 397.7K
- Earning Date
- JYD 12-04-2025
- PHGE 11-13-2025
- Dividend Yield
- JYD N/A
- PHGE N/A
- EPS Growth
- JYD N/A
- PHGE N/A
- EPS
- JYD N/A
- PHGE N/A
- Revenue
- JYD $80,305,742.00
- PHGE N/A
- Revenue This Year
- JYD N/A
- PHGE N/A
- Revenue Next Year
- JYD N/A
- PHGE N/A
- P/E Ratio
- JYD N/A
- PHGE N/A
- Revenue Growth
- JYD N/A
- PHGE N/A
- 52 Week Low
- JYD $4.50
- PHGE $0.34
- 52 Week High
- JYD $400.00
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- JYD 71.70
- PHGE 54.06
- Support Level
- JYD $4.81
- PHGE $0.55
- Resistance Level
- JYD $5.63
- PHGE $0.63
- Average True Range (ATR)
- JYD 0.52
- PHGE 0.05
- MACD
- JYD 0.18
- PHGE -0.00
- Stochastic Oscillator
- JYD 72.36
- PHGE 36.79
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is an end-to-end supply chain solution provider in China, with a focus on providing cross-border logistics services. The company offers freight forwarding services, supply chain management, and other value-added services.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).